The authors would like to thank the entire GAITWAY tumor board for their input and assistance on this case.
JonesSAnagnostouVLytleK. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med2015;7:283ra53.
VerstovsekSKantarjianHMesaRA. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med2010;363:1117–1127.
EtheridgeSLCosgroveMESangkhaeV. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood2014;123:1059–1068.
MartyCSaint-MartinCPecquetC. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood2014;123:1372–1383.
ThiedeCPrange-KrexGFreiberg-RichterJ. Buccal swabs but not mouthwash samples can be used to obtain pretransplant DNA fingerprints from recipients of allogeneic bone marrow transplants. Bone Marrow Transplant2000;25:575–577.
TsiatisACNorris-KirbyARichRG. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn2010;12:425–432.